The subscription window for the Rubicon Research IPO closed on October 13, 2025. The Rubicon Research IPO allotment status is expected to be finalised today, October 14, 2025, while the company’s shares will be listed on both BSE and NSE on October 16, 2025.
Investors can check their allotment status through the BSE, NSE, or MUFG Intime India Private Limited, the registrar to the issue.
Key Takeaways
- The Rubicon Research IPO allotment status is likely to be finalised today, October 14, 2025.
- Investors can check their allotment results online using their PAN, application number, or DP/Client ID.
- The IPO received a massive response, being subscribed 109.35 times overall.
How to Check Rubicon Research IPO Allotment Status on BSE?
To check the Rubicon Research IPO allotment status on BSE:
- Visit the BSE IPO Allotment Page.
- Select ‘Equity’ under Issue Type.
- Choose ‘Rubicon Research Ltd’ as the Issue Name.
- Enter your Application Number or PAN Number.
- Click ‘I am not a Robot’ and then ‘Search’ to view your status.
How to Check Rubicon Research IPO Allotment Status on NSE?
To verify your allotment status on NSE:
- Visit the NSE IPO Allotment Page.
- Select ‘Rubicon Research Ltd’ under Symbol.
- Enter your PAN Number and Application Number.
- Click ‘Submit’ to view your Rubicon Research IPO allotment status.
How to Check Rubicon Research IPO Allotment Status on MUFG Intime India Private Limited?
To check on the registrar’s website:
- Visit the MUFG Intime IPO Status Page.
- Under “Select Company,” choose Rubicon Research Ltd.
- Enter any of the following details such as PAN, Application Number, DP/Client ID, or Account No/IFSC.
- Click ‘Search’ to view your Rubicon Research IPO allotment status.
Rubicon Research IPO Subscription Status (Day 3)
As of October 13, 2025, the Rubicon Research IPO was subscribed 109.35 times overall.
- Retail Individual Investors (RIIs): 37.40 times
- Non-Institutional Investors (NIIs): 102.70 times
- Employees: 17.68 times
- Qualified Institutional Buyers (QIBs): 137.09 times
The strong response indicates robust investor confidence in the company’s business model and future growth prospects.
Rubicon Research IPO Details
The Rubicon Research IPO was a book-building issue worth ₹1,377.50 crore, combining a fresh issue of shares worth ₹500 crore and an offer for sale (OFS) of shares worth ₹877.50 crore.
The price band was set between ₹461 and ₹485 per share, and the minimum lot size was 30 shares, requiring a minimum investment of ₹13,830 for retail investors.
The IPO was managed by Axis Capital, IIFL Capital Services, JM Financial, and SBI Capital Markets, while MUFG Intime India Private Limited served as the registrar.
About Rubicon Research Ltd
Founded in 1999 and based in Thane, India, Rubicon Research Ltd is a specialty pharmaceutical company known for its IP-led innovation. It focuses on developing and manufacturing value-added formulations for regulated markets such as the US.
Its product range includes oral solids, liquids, nasal and inhalation products, ophthalmic solutions, topical formulations, injectables, and drug-device combinations.
The company has R&D centers in Thane (India) and Concord (Canada), along with manufacturing plants in Ambernath and Satara.
In FY 2025, Rubicon Research reported a total income of ₹1,296.2 crore, a 48.5% rise from ₹872.4 crore in FY 2024. Its Profit After Tax (PAT) increased to ₹134.36 crore, compared to ₹91.01 crore last year. The company’s EBITDA rose to ₹267.9 crore, improving its margin to 20.7%.
Disclaimer: This article is for educational purposes only. The securities or investments mentioned here are not recommendatory.
